ADWEEK on MSN3h
Mounjaro Maker Eli Lilly Swipes at Unapproved GLP-1 Rivals in Oscars Ad
Eli Lilly's bet on the Oscars shows the GLP-1 ad wars are heating up. - Eli Lilly. At the 2024 Academy Awards, Eli Lilly, the ...
Weekly Roundup: 14 Health Press Releases You Need to See
With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help ...
Irish Examiner on MSN19h
On the rebound: What are the long-term risks of Ozempic?
Ahead of World Obesity Day, we examine the impact of the game-changing drugs that control appetite. Increasingly being taken ...
Investor's Business Daily on MSN3h
Behind Hims Stock's Roller-Coaster Ride As Weight-Loss Drugs Battle Heats Up
Hims & Hers Health has blazed a red-hot streak, helped by the growing popularity of weight-loss drugs. But after a massive ...
MM&M5h
Faced with compounded drugs, Eli Lilly tells consumers to ‘be a healthy skeptic’
Eli Lilly is seeking to further cement its stance as a leader in weight loss drugs in an ad campaign calling out “unapproved” medications.
Open Source: North Carolina’s ‘data center corridor’ welcomes big tech sites for now
While attention has been on Apple’s progress (or lack thereof) in Research Triangle Park, the company continues to spend on a ...
pharmaphorum20h
FDA rejects Novo Nordisk’s weekly basal insulin
Novo Nordisk’s bid to provide a once-weekly basal insulin product for people with diabetes, reducing the number of injections needed, has hit a major hurdle in the US. The FDA sent the Danish ...